Big Data Drugs Medicine Pharma Companies 
Drug Discovery World
AUGUST 3, 2023
This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, They are called “ What’s the next step in big data and AI? ” You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.
Drug Discovery World
JULY 18, 2022
Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? Troy Groetken says that data has the ability to create personalised, predictive and preventative medicine tailored to individual patients and identified patient groups/populations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 19, 2021
The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,
Drug Discovery World
DECEMBER 27, 2023
You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. These are just some of the words that come to mind when talking about not just the drug discovery sector, but the lives of those working in and around it. He speaks about this drug discovery journey here. Developing. Listen here.
Drug Discovery World
FEBRUARY 6, 2024
As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Auransa, which harnesses available data to discover highly intractable diseases with poorly understood biology.
pharmaphorum
FEBRUARY 1, 2022
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
Drug Discovery World
AUGUST 22, 2023
Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. What are complex generics?
Expert insights. Personalized for you.
52 
Let's personalize your content